{"doi":"10.1107/s2056989024005103","title":"Synthesis and crystal structures of two racemic 2-heteroaryl-3-phenyl-2,3-dihydro-4<i>H</i>-pyrido[3,2-<i>e</i>][1,3]thiazin-4-ones","abstract":"3-Phenyl-2-(thiophen-3-yl)-2,3-dihydro-4 H -pyrido[3,2- e ][1,3]thiazin-4-one (C 17 H 12 N 2 OS 2 , 1 ) and 2-(1 H -indol-3-yl)-3-phenyl-2,3-dihydro-4 H -pyrido[3,2- e ][1,3]thiazin-4-one 0.438-hydrate (C 21 H 15 N 3 OS·0.438H 2 O, 2 ) crystallize in space groups P 2 1 / n and C 2/ c , respectively. The asymmetric unit in each case is comprised of two parent molecules, albeit of mixed chirality in the case of 1 and of similar chirality in 2 with the enantiomers occupying the neighboring asymmetric units. Structure 2 also has water molecules (partial occupancies) that form continuous channels along the b - axis direction. The thiazine rings in both structures exhibit an envelope conformation. Intermolecular interactions in 1 are defined only by C—H...O and C—H...N hydrogen bonds between crystallographically independent molecules. In 2 , hydrogen bonds of the type N—H...O between independent molecules and C—H...N(π) type, and π–π stacking interactions between the pyridine rings of symmetry-related molecules are observed.","journal":"Lateral: Revista de Cultura","year":2024,"id":498205,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9459,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":688089,"name":"Tapas K. Mal","orcid":"0000-0002-0625-2095","position":1,"is_corresponding":false},{"id":792542,"name":"Mark A. Olsen","orcid":null,"position":2,"is_corresponding":false},{"id":792007,"name":"Anthony F. Lagalante","orcid":"0000-0003-4684-0307","position":3,"is_corresponding":false},{"id":1345035,"name":"Evelyn M. Louca","orcid":null,"position":4,"is_corresponding":false},{"id":1345036,"name":"Aloura D. Gavalis","orcid":null,"position":5,"is_corresponding":false},{"id":792004,"name":"Lee J. Silverberg","orcid":"0000-0002-7353-1289","position":6,"is_corresponding":false},{"id":792008,"name":"Hemant P. Yennawar","orcid":"0000-0003-2869-1109","position":0,"is_corresponding":true}],"reference_count":18,"raw_metadata":null,"created_at":"2026-07-19T02:09:38.543544Z","pmid":"38974155","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}